Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 8/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PARL | Q9H300 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10785476 | 0.85 | MAPT (0.47) | MAPTHTR2CHTR6ALDH1A1GAA | |
| SCHEMBL27859707 | 0.76 | KMT2A (0.45) | MAPTHTR2CHTR6ALDH1A1KDM4E | |
| SCHEMBL24416127 | 0.75 | KMT2A (0.51) | MAPTHTR6ALDH1A1KDM4EKMT2A | |
| SCHEMBL7449614 | 0.75 | HTR6 (0.42) | MAPTHTR2CHTR2BHTR6ALDH1A1 | |
| SCHEMBL336837 | 0.73 | HTR2A (0.45) | MAPTHTR2CHTR6HTR2A | |
| SCHEMBL8754676 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL3547060 | 0.71 | HTR2A (0.44) | MAPTHTR2CHTR6KMT2AHTR2A | |
| SCHEMBL28710661 | 0.71 | HTR2A (0.46) | MAPTHTR2CHTR6ALDH1A1HTR2A | |
| SCHEMBL10870180 | 0.70 | HTR2C (0.39) | MAPTHTR2CHTR6ALDH1A1 | |
| SCHEMBL711807 | 0.70 | APLNR (0.50) | MAPTHTR2CHTR6KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144759-A1 | COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| EP-3056493-B1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-9585881-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| EP-3056493-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9394250-B2 | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2855452-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174937-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD (JP) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263795-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | MAPT 4808/4885HTR2C 4365/4885HTR2B 3964/4885 |
| US-10882855-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | MAPT 4808/4885HTR2C 4365/4885HTR2B 3964/4885 |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | MAPT 4808/4885HTR2C 4365/4885HTR2B 3964/4885 |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | MAPT 4808/4885HTR2C 4365/4885HTR2B 3964/4885 |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | MAPT 4808/4885HTR2C 4365/4885HTR2B 3964/4885 |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | MAPT 4808/4885HTR2C 4365/4885HTR2B 3964/4885 |
| US-20210147403-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F10, F9 | MAPT 4819/4885HTR2C 4403/4885HTR2B 4054/4885 |
| US-20220144759-A1 | COMPOUND | SFXN3, SFXN1, CBR3 | MAPT 4522/4885HTR2C 1978/4885HTR2B 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.